MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice.
about
Immunological Evaluation of Recent MUC1 Glycopeptide Cancer VaccinesIdentification of new MUC1 epitopes using HLA-transgenic animals: implication for immunomonitoring.Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes.Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.Crystal structures of H-2Db in complex with the LCMV-derived peptides GP92 and GP392 explain pleiotropic effects of glycosylation on antigen presentation and immunogenicity.Tool for Rapid Analysis of Glycopeptide by Permethylation via One-Pot Site Mapping and Glycan Analysis.Principles of mucin structure: implications for the rational design of cancer vaccines derived from MUC1-glycopeptides.Anti-MUC1 aptamer: A potential opportunity for cancer treatment.Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice.Oncolysate-loaded Escherichia coli bacterial ghosts enhance the stimulatory capacity of human dendritic cells.
P2860
Q26740513-C94190BA-C780-40FC-8176-AFCCE308672DQ33876878-C586E0F8-6EF8-4663-B8E8-B9E37979FAFCQ37290676-B9CE4F6B-6899-4D05-A9E3-874CE7A47FE6Q37706835-8E3585D2-F1A7-494A-B85A-49BD813DA2BAQ38948901-42AB68F8-6DAF-47FB-AB8D-D40823EA26E0Q47144276-D087766D-6E6F-4B3F-B433-752B2ED939D6Q47785877-A1098DC5-D063-48D1-9AD7-3AE65835CE75Q47902181-52318522-581A-4957-96D0-C3388E955F58Q48009199-6E02490D-534E-490B-8B84-F09D75F95B09Q48120406-AE92333C-052B-4A89-B520-9F4E90F9438DQ50545957-90A38060-3985-4B97-82E9-305B9A676076
P2860
MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
MUC1 Vaccines, Comprised of Gl ...... rowth in MUC1 Transgenic Mice.
@ast
MUC1 Vaccines, Comprised of Gl ...... rowth in MUC1 Transgenic Mice.
@en
type
label
MUC1 Vaccines, Comprised of Gl ...... rowth in MUC1 Transgenic Mice.
@ast
MUC1 Vaccines, Comprised of Gl ...... rowth in MUC1 Transgenic Mice.
@en
prefLabel
MUC1 Vaccines, Comprised of Gl ...... rowth in MUC1 Transgenic Mice.
@ast
MUC1 Vaccines, Comprised of Gl ...... rowth in MUC1 Transgenic Mice.
@en
P2093
P2860
P50
P1433
P1476
MUC1 Vaccines, Comprised of Gl ...... Growth in MUC1 Transgenic Mice
@en
P2093
Cathy S Madsen
Dominique B Hoelzinger
Dustin B McCurry
Heidi E Kosiorek
Judy M Bradley
Latha B Pathangey
Nitin T Supekar
Peter A Cohen
Priyanka P Trivedi
P2860
P304
P356
10.1371/JOURNAL.PONE.0145920
P407
P577
2016-01-20T00:00:00Z